Intellia Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
The following table describes for the three months ended June 30, 2025 each trading arrangement under which the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| John M. Leonard (President, CEO) | Adoption (April 2, 2025) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of (a) February 3, 2026; (b) the date on which the aggregate number of shares of stock sold pursuant to this trading plan reaches 88,146 shares; and (c) the date on which the plan holder gives notice to terminate the plan. | 88,146 |
| Muna Bhanji (Director) | Terminated (May 8, 2025) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of (a) June 20, 2025; (b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and (c) the date on which the plan holder gives notice to terminate the plan. | 3,094 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.